Literature DB >> 33873073

Investigation of the therapeutic effect of Yinchen Wuling Powder on CCl4-induced hepatic fibrosis in rats by 1H NMR and MS-based metabolomics analysis.

Yumeng Zhang1, Min Zhao1, Yangyang Liu2, Tingting Liu1, Chunjie Zhao3, Miao Wang4.   

Abstract

Hepatic fibrosis (HF) is a typical consequence of various chronic liver diseases, and there is still no ideal drug for its treatment. Yinchen Wuling Powder (YCWLP), a famous traditional Chinese medicine prescription, is effective for the treatment of icteric hepatitis, hepatic fibrosis, non-alcoholic fatty liver disease and other liver diseases in clinical practices, however, the underlying mechanisms of YCWLP on HF is still unclear. In this study, 1H NMR and MS-based metabolomics analysis along with body weight change, serum liver function indexes, serum liver fibrosis index and histopathological observations of liver were applied to evaluate the therapeutic effect of YCWLP on hepatic fibrosis and the mechanism associated with this. The results of the pharmacodynamics study show that YCWLP has a significant therapeutic effect on hepatic fibrosis. As for the metabolomics research, 7 metabolites in the plasma samples, 28 in the urine samples and 6 in the liver samples were significantly altered due to the protective effect of YCWLP on CCl4-induced hepatic fibrosis. These endogenous metabolites are involved in amino acid metabolism, carbohydrate metabolism, glycerophospholipid metabolism and gut bacteria metabolism. These findings suggest that YCWLP could treat hepatic fibrosis by promoting urea circulation and reducing blood ammonia accumulation, improving carbohydrate metabolism and reducing oxidative stress, improving glycerophospholipid metabolism and protecting cell membrane, and regulating intestinal flora metabolism.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  (1)H NMR; Hepatic fibrosis; Metabolomics; UPLC-MS; Yinchen Wuling Powder

Year:  2021        PMID: 33873073     DOI: 10.1016/j.jpba.2021.114073

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  3 in total

1.  Detoxification II Prescription Suppresses the Th-17/IL-17 Inflammatory Axis to Improve the Liver Function of ACLF-Rats via Inactivating the P38MAPK Pathway.

Authors:  Qinglan Shi; Wenjie Bai; Dewen Mao; Yueqiao Chen; Kejing Wang; Hua Qiu; Jinyu Wu
Journal:  J Healthc Eng       Date:  2021-12-03       Impact factor: 2.682

2.  Tormentic Acid Ameliorates Hepatic Fibrosis in vivo by Inhibiting Glycerophospholipids Metabolism and PI3K/Akt/mTOR and NF-κB Pathways: Based on Transcriptomics and Metabolomics.

Authors:  Xing Lin; Yuanyuan Wei; Yan Li; Yuhua Xiong; Bin Fang; Cuiyu Li; Quanfang Huang; Renbin Huang; Jinbin Wei
Journal:  Front Pharmacol       Date:  2022-03-11       Impact factor: 5.810

3.  Revealing the Mechanism of Huazhi Rougan Granule in the Treatment of Nonalcoholic Fatty Liver Through Intestinal Flora Based on 16S rRNA, Metagenomic Sequencing and Network Pharmacology.

Authors:  Yingying Liu; Yingying Tan; Jiaqi Huang; Chao Wu; Xiaotian Fan; Antony Stalin; Shan Lu; Haojia Wang; Jingyuan Zhang; Fanqin Zhang; Zhishan Wu; Bing Li; Zhihong Huang; Meilin Chen; Guoliang Cheng; Yanfang Mou; Jiarui Wu
Journal:  Front Pharmacol       Date:  2022-04-26       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.